CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 9 target
Drug / intervention
HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2biological
Likely dose
HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00633724
NCT00633724Phase 1Completed
CompareCT.gov

Phase I Study of Multiple-vaccine Therapy Including Antiangiogenic Vaccine Using Epitope Peptide Restricted to HLA-A*2402 in Treating Patients With Unresectable or Recurrent Non-small Cell Lung Cancer

Fukushima Medical University·interventional·Posted Mar 12, 2008·Updated Aug 15, 2013

In Brief

A Phase 1 clinical trial evaluating HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2 for Non Small Cell Lung Cancer. Completed, enrolled 9 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety, tolerability, immune response and clinical response of different doses of HLA-A\*2402 restricted epitope peptides URLC10, TTK, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesJapan
CollaboratorsHuman Genome Center, Institute of Medical Science, University of Tokyo

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 12, 2008
Enrollment StartMay 1, 2007
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 18.3 years ago

Interventions

HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2biological

Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 0.5mg, 1.0mg and 3.0mg.